| Code | Description | Claims | Beneficiaries | Total Paid |
|---|
| 99285 |
Emergency department visit for the evaluation and management, high severity with immediate threat to life |
3,120 |
2,484 |
$1.46M |
| 97110 |
Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion |
10,638 |
2,882 |
$1.13M |
| 99284 |
Emergency department visit for the evaluation and management, high severity |
4,516 |
3,779 |
$1.06M |
| 99283 |
Emergency department visit for the evaluation and management, moderate severity |
5,115 |
4,088 |
$918K |
| 80053 |
Comprehensive metabolic panel |
5,029 |
3,790 |
$704K |
| 85025 |
Blood count; complete (CBC), automated, and automated differential WBC count |
8,611 |
6,131 |
$642K |
| 74177 |
Computed tomography, abdomen and pelvis; with contrast material |
762 |
597 |
$440K |
| 77067 |
Screening mammography, bilateral, including computer-aided detection |
2,452 |
2,108 |
$419K |
| 80048 |
Basic metabolic panel (calcium, ionized) |
3,533 |
2,740 |
$403K |
| Q9967 |
Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml |
1,607 |
1,258 |
$351K |
| 99282 |
Emergency department visit for the evaluation and management, low to moderate severity |
1,693 |
1,192 |
$330K |
| 97140 |
Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) |
3,711 |
1,196 |
$311K |
| 93005 |
Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report |
2,621 |
2,008 |
$267K |
| 82248 |
|
2,654 |
2,071 |
$266K |
| 96374 |
Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance |
1,756 |
1,370 |
$251K |
| 96375 |
Therapeutic injection; each additional sequential IV push |
1,188 |
825 |
$222K |
| 71046 |
Radiologic examination, chest; 2 views |
2,668 |
2,138 |
$217K |
| J7030 |
Infusion, normal saline solution , 1000 cc |
896 |
658 |
$207K |
| 87624 |
Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types |
1,804 |
1,422 |
$188K |
| 88175 |
Cytopathology, cervical or vaginal, any reporting system; collected in preservative fluid, automated thin layer |
2,620 |
2,099 |
$181K |
| J2405 |
Injection, ondansetron hydrochloride, per 1 mg |
957 |
606 |
$181K |
| 87491 |
Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe |
2,039 |
1,556 |
$174K |
| 87591 |
Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe |
2,028 |
1,547 |
$173K |
| 81003 |
|
1,948 |
1,619 |
$170K |
| G0480 |
Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed |
972 |
714 |
$167K |
| 80061 |
Lipid panel |
2,501 |
2,200 |
$165K |
| 96361 |
Intravenous infusion, hydration; each additional hour |
1,016 |
770 |
$161K |
| 83690 |
|
1,396 |
1,088 |
$160K |
| 84484 |
|
1,712 |
1,168 |
$155K |
| G0378 |
Hospital observation service, per hour |
331 |
203 |
$144K |
| 85027 |
|
2,992 |
2,283 |
$144K |
| 80050 |
General health panel |
567 |
520 |
$135K |
| 82948 |
|
588 |
277 |
$133K |
| U0003 |
Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r |
920 |
857 |
$126K |
| 80307 |
Drug test(s), presumptive, any number of drug classes; immunoassay |
888 |
622 |
$125K |
| 83735 |
|
1,143 |
757 |
$123K |
| 87801 |
Infectious agent detection by nucleic acid; amplified probe, multiple organisms |
579 |
356 |
$122K |
| 76856 |
Ultrasound, pelvic (nonobstetric), real time with image documentation; complete |
390 |
275 |
$117K |
| 76830 |
Ultrasound, transvaginal |
514 |
376 |
$114K |
| 82306 |
Vitamin D; 25 hydroxy, includes fraction(s), if performed |
1,127 |
969 |
$111K |
| 85610 |
|
1,379 |
821 |
$110K |
| 96372 |
Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular |
694 |
362 |
$107K |
| 87086 |
Culture, bacterial; quantitative colony count, urine |
1,827 |
1,466 |
$106K |
| 81001 |
|
1,333 |
1,079 |
$99K |
| 70450 |
Computed tomography, head or brain; without contrast material |
560 |
475 |
$90K |
| 87481 |
|
596 |
354 |
$85K |
| 83036 |
Hemoglobin; glycosylated (A1C) |
1,947 |
1,689 |
$82K |
| 81514 |
|
186 |
180 |
$81K |
| J1170 |
Injection, hydromorphone, up to 4 mg |
337 |
165 |
$80K |
| 86850 |
|
759 |
534 |
$79K |
| 88305 |
Level IV - Surgical pathology, gross and microscopic examination |
363 |
232 |
$78K |
| 97161 |
|
698 |
530 |
$78K |
| 87661 |
Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe |
649 |
386 |
$77K |
| 84443 |
Thyroid stimulating hormone (TSH) |
1,796 |
1,487 |
$76K |
| 70553 |
Magnetic resonance imaging, brain; without contrast material, followed by contrast material and further sequences |
51 |
50 |
$71K |
| 96376 |
|
289 |
163 |
$70K |
| H0035 |
Mental health partial hospitalization, treatment, less than 24 hours |
80 |
14 |
$69K |
| 86900 |
|
766 |
539 |
$66K |
| 77063 |
Screening digital breast tomosynthesis, bilateral |
1,648 |
1,632 |
$61K |
| 36415 |
Collection of venous blood by venipuncture |
4,247 |
3,400 |
$59K |
| 86901 |
|
766 |
539 |
$59K |
| 86803 |
|
702 |
579 |
$58K |
| G1004 |
Clinical decision support mechanism national decision support company, as defined by the medicare appropriate use criteria program |
589 |
448 |
$58K |
| J2704 |
Injection, propofol, 10 mg |
385 |
275 |
$54K |
| J1885 |
Injection, ketorolac tromethamine, per 15 mg |
478 |
340 |
$53K |
| J2250 |
Injection, midazolam hydrochloride, per 1 mg |
239 |
173 |
$50K |
| 86780 |
|
679 |
571 |
$48K |
| J3490 |
Unclassified drugs |
269 |
154 |
$48K |
| 87389 |
Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies |
744 |
633 |
$46K |
| 93306 |
Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete |
52 |
39 |
$44K |
| 76642 |
|
240 |
239 |
$41K |
| 97530 |
Therapeutic activities, direct patient contact, each 15 minutes |
292 |
66 |
$40K |
| 87340 |
|
548 |
438 |
$40K |
| A9585 |
Injection, gadobutrol, 0.1 ml |
366 |
279 |
$39K |
| 76801 |
|
122 |
114 |
$37K |
| J3010 |
Injection, fentanyl citrate, 0.1 mg |
147 |
115 |
$32K |
| 87081 |
|
225 |
155 |
$26K |
| 73721 |
Magnetic resonance imaging, any joint of lower extremity; without contrast material |
43 |
37 |
$22K |
| 72148 |
Magnetic resonance imaging, lumbar spine; without contrast material |
38 |
38 |
$22K |
| 70551 |
Magnetic resonance imaging, brain; without contrast material |
30 |
12 |
$21K |
| 85651 |
|
499 |
297 |
$19K |
| J2270 |
Injection, morphine sulfate, up to 10 mg |
222 |
143 |
$19K |
| 82728 |
|
217 |
214 |
$19K |
| 82607 |
|
290 |
287 |
$19K |
| 84703 |
|
193 |
147 |
$18K |
| 96365 |
Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour |
102 |
77 |
$18K |
| 94640 |
Pressurized or nonpressurized inhalation treatment for acute airway obstruction |
290 |
102 |
$17K |
| 87088 |
|
413 |
330 |
$17K |
| U0005 |
Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 |
229 |
218 |
$17K |
| 87480 |
|
226 |
192 |
$16K |
| 80076 |
|
146 |
69 |
$16K |
| 87502 |
Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets |
162 |
124 |
$15K |
| 73030 |
|
160 |
115 |
$14K |
| 73562 |
|
201 |
138 |
$14K |
| C9803 |
Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source |
99 |
93 |
$12K |
| 72100 |
|
92 |
81 |
$11K |
| 86787 |
|
121 |
91 |
$11K |
| 83605 |
|
93 |
72 |
$11K |
| 82565 |
|
591 |
347 |
$10K |
| 99214 |
Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity |
73 |
61 |
$10K |
| 83540 |
|
167 |
167 |
$10K |
| 0241U |
Neonatal screening for hereditary disorders, genomic sequence analysis panel |
55 |
53 |
$10K |
| 87637 |
Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV |
46 |
42 |
$10K |
| 81025 |
|
138 |
101 |
$9K |
| 83550 |
|
93 |
93 |
$9K |
| 87186 |
|
87 |
68 |
$8K |
| J1100 |
Injection, dexamethasone sodium phosphate, 1 mg |
115 |
88 |
$8K |
| 83880 |
|
54 |
29 |
$8K |
| 87510 |
|
226 |
192 |
$7K |
| 87660 |
|
226 |
192 |
$7K |
| 86762 |
|
122 |
90 |
$7K |
| 72125 |
Computed tomography, cervical spine; without contrast material |
50 |
40 |
$7K |
| 84100 |
|
120 |
43 |
$7K |
| 96360 |
Intravenous infusion, hydration; initial, 31 minutes to 1 hour |
44 |
38 |
$6K |
| 86140 |
|
118 |
92 |
$6K |
| 84702 |
|
47 |
41 |
$6K |
| 72141 |
|
13 |
13 |
$6K |
| 84439 |
|
117 |
115 |
$6K |
| 99281 |
Emergency department visit for the evaluation and management, self-limited or minor |
29 |
16 |
$5K |
| 73560 |
|
69 |
25 |
$5K |
| 76705 |
Ultrasound, abdominal, real time with image documentation; limited |
24 |
24 |
$3K |
| 73502 |
|
52 |
41 |
$3K |
| 97162 |
|
42 |
27 |
$3K |
| 76816 |
Ultrasound, pregnant uterus, real time with image documentation, follow-up |
14 |
13 |
$3K |
| 11042 |
Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm |
15 |
12 |
$2K |
| 84520 |
|
172 |
71 |
$2K |
| J0690 |
Injection, cefazolin sodium, 500 mg |
28 |
20 |
$2K |
| 84481 |
|
25 |
24 |
$2K |
| 73630 |
|
19 |
13 |
$1K |
| 82105 |
|
25 |
24 |
$1K |
| 85379 |
|
17 |
14 |
$1K |
| 82947 |
|
41 |
25 |
$1K |
| 87077 |
|
35 |
25 |
$1K |
| 84460 |
|
32 |
27 |
$1K |
| G0463 |
Hospital outpatient clinic visit for assessment and management of a patient |
51 |
28 |
$1K |
| G8979 |
Mobility: walking & moving around functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting |
62 |
27 |
$1K |
| 84450 |
|
29 |
26 |
$1K |
| 80051 |
|
27 |
13 |
$994.63 |
| J2060 |
Injection, lorazepam, 2 mg |
15 |
12 |
$755.50 |
| 87651 |
Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe |
20 |
20 |
$739.73 |
| 85730 |
|
24 |
17 |
$676.11 |
| 87070 |
|
18 |
13 |
$490.86 |
| 87205 |
|
19 |
14 |
$414.41 |
| G8978 |
Mobility: walking & moving around functional limitation, current status, at therapy episode outset and at reporting intervals |
17 |
12 |
$349.05 |
| J7040 |
Infusion, normal saline solution, sterile (500 ml = 1 unit) |
21 |
12 |
$346.35 |
| 82950 |
|
12 |
12 |
$303.66 |
| 82310 |
|
20 |
13 |
$273.83 |